Biolinerx Stock Earnings Reports

BioLineRx has initiated first‑in‑human dosing of GLIX1 in a Phase I/IIa trial for glioblastoma (GBM), with three leading academic centers participating (NYU Langone, Northwestern, Moffitt) and periodic updates planned in H2 2026 and dose‑escalation results expected in 2027. GLIX1 is an oral small molecule that restores TET2 activity, crosses the blood‑brain barrier, and showed encouraging preclinical efficacy including activity in temozolomide‑resistant GBM models and synergistic rationale for combining with PARP inhibitors. In pancreatic cancer (PDAC), BioLineRx retains rights to motixafortide in PDAC; the Columbia‑led randomized Phase IIb CheMo4METPANC trial is enrolling on schedule with a prespecified interim futility analysis planned for later in 2026 (at 40% PFS events). Commercially, Ayrmid’s APHEXDA sales increased to $2.5M in Q1 2026 (from $1.4M in Q1 2025), generating $0.5M of royalties to BioLineRx. Financial highlights for Q1 2026: revenues $0.5M, R&D expenses $2.5M (up due to GLIX1), G&A $0.9M, net loss $2.6M, and cash and equivalents of $17.4M, which management says funds operations into the first half of 2027. Management indicated no current recruitment issues for the recurrent GBM population but declined to disclose specific site activation status or clinical dose levels at this time.